A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD

Inclusion Criteria:

• Age ≥ 12 at Day 1.

• Diagnosis of AD according to American Academy of Dermatology (AAD) ConsensusCriteria (2014) that has been present for at least 12 months.

• History of inadequate response to Topical Corticosteroids (TCS) of medium to higherpotency (with or without topical calcineurin inhibitors [TCI]).

• Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ≥ 3at screening and pre-randomization.

• Eczema Area and Severity Index (EASI) score ≥ 16 at initial at screening andpre-randomization.

• ≥ 10% body surface area (BSA) of AD involvement at screening and pre-randomization.

Exclusion Criteria:

• Treatment with a biological product within 12 weeks or 5 half-lives, whichever islonger, prior to day 1 pre-randomization.

• Treatment with any of the following medications or therapies within 5 half-livesprior to day 1 pre-randomization:

1. Systemic corticosteroids

2. Non-biologic, non-targeted systemic immunosuppressants

3. Oral or Topical Janus kinase inhibitors

• Treatment with any of the following medications or therapies within 1 week beforeday 1 pre-randomization:

1. Topical phosphodiesterase 4 (PDE4) inhibitors

2. Other topical immunosuppressive agents (not including TCS/TCI)

3. Combination topical agents containing any of the above components